These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

781 related items for PubMed ID: 18585634

  • 21. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D, von Wietersheim J, Pflüger H, Steiner H, Doehn C, Büttner H, Böhle A, Kausch I.
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [Abstract] [Full Text] [Related]

  • 22. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N.
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [Abstract] [Full Text] [Related]

  • 23. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS.
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [Abstract] [Full Text] [Related]

  • 24. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
    Järvinen R, Kaasinen E, Rintala E, Group TF.
    Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
    [Abstract] [Full Text] [Related]

  • 25. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 26. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
    Bretheau D, Lechevallier E, Rossi D, Albert P, de Fromont M, Coulange C.
    Prog Urol; 1993 Feb; 3(4):608-17. PubMed ID: 8401621
    [Abstract] [Full Text] [Related]

  • 27. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R.
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [Abstract] [Full Text] [Related]

  • 28. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM.
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [Abstract] [Full Text] [Related]

  • 29. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Soloway MS, Sofer M, Vaidya A.
    J Urol; 2002 Apr; 167(4):1573-83. PubMed ID: 11912367
    [Abstract] [Full Text] [Related]

  • 30. [Treatment of superficial tumors of the bladder].
    Patard JJ, Chopin D, Abbou CC.
    Cancer Radiother; 1998 Apr; 2 Suppl 1():19s-26s. PubMed ID: 9749073
    [Abstract] [Full Text] [Related]

  • 31. [Results of treatment of superficial vesical tumors by transurethral resection alone and transurethral resection followed by an intravesical instillation of Calmette-Guerin bacillus].
    Chopin D, Hoznek A, Colombel M, Surig-Biscarat MH, Antiphon P, Hervé JM, Bellot J, Auvert J, Abbou CC.
    Ann Urol (Paris); 1990 Apr; 24(5):435-40. PubMed ID: 2252358
    [Abstract] [Full Text] [Related]

  • 32. The management of superficial bladder cancer.
    Dalbagni G.
    Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
    [Abstract] [Full Text] [Related]

  • 33. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 34. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 35. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 36. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C, Minocchi L, Arecchi S, Nicolucci D, Porcelli C, D'orazi V, Greco L, Stio F, Martino G, Messinetti S.
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract] [Full Text] [Related]

  • 37. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).
    Oosterlinck W, Kirkali Z, Sylvester R, da Silva FC, Busch C, Algaba F, Collette S, Bono A.
    Eur Urol; 2011 Mar; 59(3):438-46. PubMed ID: 21156335
    [Abstract] [Full Text] [Related]

  • 38. Overview of treatment of superficial bladder cancer.
    Soloway MS.
    Urology; 1985 Oct; 26(4 Suppl):18-26. PubMed ID: 4049626
    [Abstract] [Full Text] [Related]

  • 39. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC, Steinberg GD.
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [Abstract] [Full Text] [Related]

  • 40. Editorial comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Mostafid H.
    Int J Urol; 2010 Sep; 17(9):766-7. PubMed ID: 20727047
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.